Jentadueto Available for Type 2 Diabetes

Share this content:
Jentadueto (linagliptin&metformin HCl) 2.5/500mg; 2.5/850mg; 2.5/1000mg tabs by Boehringer-Ingelheim
Jentadueto (linagliptin&metformin HCl) 2.5/500mg; 2.5/850mg; 2.5/1000mg tabs by Boehringer-Ingelheim

Boehringer Ingelheim and Lilly announced that Jentadueto (linagliptin/metformin) is now available as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. Jentadueto is a fixed-dose combination product containing linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a biguanide. Linagliptin increases the concentrations of active incretin hormones, which stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation. Metformin improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial glucose.

Jentadueto is available in 2.5mg/500mg, 2.5mg/850mg, and 2.5mg/1000mg dosage strength tablets and come in 60- and 180-count bottles.

For more information, call (800) 542-6257 or visit

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters